XBiotech Announces Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study in The Journal of Investigative Dermatology
Report Highlights Efficacy of anti-IL-1 alpha Antibody Therapy in the Treatment of the Debilitating Skin Disease, Hidradenitis Suppurativa
AUSTIN, Texas, Dec. 04, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today the publication of data from its randomized phase 2 study evaluating XBiotech's True Human(TM) antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS). The results have been published online as an article in press in the prestigious, peer-reviewed Journal of Investigative Dermatology in a manuscript titled, "MABp1 Targeting Interleukin-1alpha for Moderate to Severe Hidradenitis Suppurativa not Eligible for Adalimumab: A Randomized Study." The article is planned to be featured in an upcoming print issue of the journal.
"This study features not only the clinical efficacy of MABp1 but also demonstrates its mechanism of action, which is something that is truly unique for a candidate drug treatment for HS," commented Prof. Evangelos Giamarellos-Bourboulis, M.D., Ph.D., who supervises the Outpatients Department for HS of the 4th Department of Medicine at Attikon University Hospital in Greece where the featured study was conducted and also served as the Principal Investigator of the study. He further stated, "MABp1 represents a potential breakthrough in the treatment of HS as it could cover an overtly unmet need for patients either failing or not eligible for adalimumab, the only registered biological treatment of HS to date. Data acquired by this study shed light to the promising efficacy of MABp1 even for naïve patients."
The publication highlights the efficacy of MABp1, in which the study's primary endpoint was met in 60% of MABp1 treated patients compared to 10% of placebo patients (odds ratio 13.50, 95% confidence intervals 1.19-152.51; p=0.035). The clinical efficacy of MABp1 was maintained until week 24 (12 weeks after discontinuation of treatment) at which time point, no patients treated with placebo had a positive HiSCR score (0%) compared to four out of 10 patients (40%) treated with MABp1. Treatment with MABp1 was also accompanied by better patient-reported outcomes. Decrease of the visual analogue scale (VAS) was found in 30% of placebo patients compared with 70% of patients treated with MABp1.
About the Study
The 20-patient double-blind, placebo-controlled study was designed to evaluate the safety and efficacy of MABp1, the Company's True Human antibody targeting interleukin-1 alpha (IL-1alpha), in patients with HS not eligible for anti-TNF therapy. Patients were randomized 1:1 to receive either MABp1 or placebo every 2 weeks for 12 weeks. Patients in the study underwent primary assessment of efficacy using Hidradenitis Suppurativa Clinical Response (HiSCR) scores at 12 weeks, continued by a follow up phase to assess time to relapse after an additional 12 weeks without therapy. Efficacy measures include assessment of HiSCR scores, a validated method for evaluating efficacy in HS patients, as well as quality of life assessment and ultrasonographic evaluation.
About Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disorder affecting areas rich in apocrine glands. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus. This process occurs repeatedly leading to formation of deep sinus tracts and painful dermal abscesses 1,2. Therefore, HS is often devastating for patients with significant impact on quality of life 3. The Dermatology Quality Life Index (DQLI) for HS is 8.9, being higher than any other skin disorder 4. Traditional treatments comprise of antibiotics, antiandrogens and surgery. The global prevalence for HS is estimated at up to 4% of the population 2.
About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
1 Revuz J. Hidradenitis suppurativa.
J Eur Acad Dermatol Venereol 2009; 23: 985-998.
2 Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3. doi: 10.1016/j.jaad.2008.11.911.
3 Vasquez BG, Alikhan A, Weaver, AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013 Jan;133(1):97-103. doi: 10.1038/jid.2012.255. Epub 2012 Aug 30.
4 Révuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 695-701.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival24.9.2018 20:26 | Pressemelding
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, professor in the Departments of Radiation Oncology and Health Policy, Management and Evaluation at the University of Toronto and staff radiation oncologist at Princess Margaret Cancer Centre, summarized the wide-ranging study topics presented in today’s conference, from significant clinical research findings to gender differences in lung cancer survival. IMpower132 study shows atezolizumab in combination with carboplatin and pemetrexed improves survival in Stage IV non-squamous NSCLC Recent findings from the IMpower132 study, presented by Vassiliki A. Papadimitrakopoulou, M.D., chief of the Section of Thoracic Medical Oncology at MD Anderson Cancer Center, demonstrate that the use of atezolizumab in combination with carboplatin as first-l
Bombardier CRJ Series Certified for Higher Maintenance Intervals24.9.2018 18:00 | Pressemelding
MONTREAL, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that the Federal Aviation Agency (FAA) has granted approval for the maintenance intervals escalation of the CRJ700, CRJ900 and CRJ1000 aircraft. The line maintenance interval (A-check) is extended to 800 flight hours, and the heavy maintenance interval (C-check) at 8,000 flight hours. “With the longest maintenance intervals on the regional jet market, the CRJ aircraft family continues to deliver more value to operators, along with its excellent reliability and its proven outstanding operational capability”, said Charles Comtois, Head of CRJ Series Program, Bombardier Commercial Aircraft. “We are thrilled that our operators are benefitting from our continuous improvement mindset as with this evolution, the CRJ Series operators can now take advantage of 14 per cent less maintenance days, meaning more days of revenue flying.” The maintenance intervals have doubled since the launch of the CRJ aircra
Mitratech Launches Latest TeamConnect ELM Innovations at Interact24.9.2018 16:01 | Pressemelding
Full Integration of TAP Workflow Automation, New Business Intelligence Module and Deeper MS Office Integration Enhance Collaboration and Reporting AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Mitratech released the next version of TeamConnect at Interact, the company’s customer-focused annual event in Austin. The latest version of the award-winning ELM platform now includes: Full Integration with TAP Workflow Automation Business Intelligence reporting Deeper Microsoft® Office integration Today, TeamConnect integrates with TAP Workflow Automation and redeﬁnes every aspect of data analytics and reporting through the TeamConnect Business Intelligence (BI) module. With the addition of the TAP Workflow Automation Platform recently acquired in April, Mitratech’s TeamConnect platform can now bring people, processes, and information together like never before, by leveraging TAP’s easy-to-use workflow automation engine to extend TeamConnect’s reach across the entire enterprise. TAP was des
Colliers International Appoints Christopher Galvin to Its Board of Directors24.9.2018 16:00 | Pressemelding
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) (“Colliers”) today announced the appointment of Mr. Christopher Galvin to its Board of Directors, effective immediately. Mr. Galvin previously served as the Chairman and co-founder of Harrison Street Real Estate Capital LLC, one of the largest real estate investment firms dedicated to the education, healthcare and storage sectors. Colliers acquired a 75% interest in Harrison Street earlier this year. Mr. Galvin presently serves as Chairman or board member of Uniquesoft, LLC, Velocidata, evolve24, Three Ocean Partners and MCR-Aerodyne, Inc. Additionally, Mr. Galvin is a member of the Executive Committee of Northwestern University’s Board of Trustees, and the Boards of Trustees of the American Enterprise Institute, the Legion D’honneur, and Tsinghua University School of Economics Management Advisory Council, among others. Mr. Galvin has previously served in a variety of executive leadersh
Seclore Offers the First Open Data-Centric Security Platform24.9.2018 15:00 | Pressemelding
Easily leverage best-of-breed data protection solutions and existing Enterprise systems for an automation-first approach to data protection and tracking MILPITAS, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Seclore, providers of the industry’s first browser-based Rights Management solution, today announced the release of Seclore’s Data-Centric Security Platform (DCSP). A first-of-its kind platform, it is designed to give customers an open, integrated and automated Data-Centric Security approach to discover, identify, protect and track sensitive data. The automation and agility of the platform enables organizations to remove the limitations of point solutions while increasing the security of sensitive data. At the core of the Seclore DCSP, is the Seclore Unified Policy Manager, the central engine for orchestrating policy management, identity federation, and usage data consolidation. Learn more about the Seclore Data-Centric Security Platform “As data grows exponentially and is stored and
XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa24.9.2018 14:30 | Pressemelding
AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it had completed enrollment in the U.S. for its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). Enrollment has exceeded the planned limit for the study in just over two months, significantly outpacing expectations. XBiotech plans to accept a limited number of additional patients in Europe prior to study completion. John Simard, Chairman & CEO of XBiotech, commented, “We are very pleased by the enrollment rate we have seen in this study. Patient availability has been well beyond what was predicted. I believe this speaks to the need for new treatment options for this debilitating disease. I want to thank all of the patients and clinical sites for their ongoing participation in this study.” The phase 2 study involves a 13-week treatment regimen. Two groups of patients are being treated
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom